Adage Capital Partners
XLRN

Adage Capital Partners’s Acceleron Pharma XLRN Stock Holding History

Adage Capital Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-350,000
Closed -$43.9M – 1119
2021
Q2 		$43.9M Buy
+350,000
New +$44.1M 0.09% 242
2018
Q3 		– Sell
-108,500
Closed -$5.26M – 780
2018
Q2 		$5.26M Buy
+108,500
New +$3.95M 0.01% 644
2016
Q4 		– Sell
-169,500
Closed -$6.13M – 744
2016
Q3 		$6.13M Sell
169,500
-118,000
-41% -$3.91M 0.02% 591
2016
Q2 		$9.77M Sell
287,500
-100,000
-26% -$3.25M 0.03% 518
2016
Q1 		$10.2M Hold
387,500
– – 0.03% 509
2015
Q4 		$18.9M Sell
387,500
-531,555
-58% -$19.1M 0.05% 383
2015
Q3 		$22.9M Sell
919,055
-255,945
-22% -$7.69M 0.06% 354
2015
Q2 		$37.2M Sell
1,175,000
-25,000
-2% -$807K 0.09% 278
2015
Q1 		$45.7M Sell
1,200,000
-572,406
-32% -$22.8M 0.11% 243
2014
Q4 		$69.1M Buy
1,772,406
+25,000
+1% +$871K 0.17% 161
2014
Q3 		$52.8M Buy
1,747,406
+226,740
+15% +$6.39M 0.13% 205
2014
Q2 		$51.7M Buy
1,520,666
+178,469
+13% +$5.97M 0.13% 203
2014
Q1 		$46.3M Buy
1,342,197
+817,197
+156% +$36.9M 0.13% 215
2013
Q4 		$20.8M Buy
+525,000
New +$12.7M 0.06% 392

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Adage Capital Partners's XLRN Position: Q3 2021 in Review

Adage Capital Partners sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 350,000 shares — an estimated $43.9M sold.

Adage Capital Partners first reported a position in XLRN in Q4 2013 and held it in 14 quarters. The position peaked at $69.1M in Q4 2014. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

  • Adage Capital Partners reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
  • Adage Capital Partners sold 350,000 Acceleron Pharma shares in Q3 2021, an estimated $43.9M.
  • Adage Capital Partners first reported a position in Acceleron Pharma in Q4 2013 and held it in 14 quarters.
  • Adage Capital Partners's Acceleron Pharma position peaked at $69.1M in Q4 2014.
  • 330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Adage Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.